- Home
- OP vs LIXT Comparison
OP vs LIXT Comparison
Compare OP & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- LIXT
- Stock Information
- Founded
- OP 2021
- LIXT 2005
- Country
- OP Greece
- LIXT United States
- Employees
- OP N/A
- LIXT N/A
- Industry
- OP
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- LIXT Health Care
- Exchange
- OP Nasdaq
- LIXT Nasdaq
- Market Cap
- OP 14.3M
- LIXT 12.4M
- IPO Year
- OP N/A
- LIXT N/A
- Fundamental
- Price
- OP $1.24
- LIXT $6.01
- Analyst Decision
- OP
- LIXT
- Analyst Count
- OP 0
- LIXT 0
- Target Price
- OP N/A
- LIXT N/A
- AVG Volume (30 Days)
- OP 1.2M
- LIXT 165.5K
- Earning Date
- OP 12-02-2025
- LIXT 11-11-2025
- Dividend Yield
- OP N/A
- LIXT N/A
- EPS Growth
- OP N/A
- LIXT N/A
- EPS
- OP N/A
- LIXT N/A
- Revenue
- OP $19,435,000.00
- LIXT N/A
- Revenue This Year
- OP N/A
- LIXT N/A
- Revenue Next Year
- OP N/A
- LIXT N/A
- P/E Ratio
- OP N/A
- LIXT N/A
- Revenue Growth
- OP N/A
- LIXT N/A
- 52 Week Low
- OP $1.07
- LIXT $0.64
- 52 Week High
- OP $79.25
- LIXT $6.26
- Technical
- Relative Strength Index (RSI)
- OP 32.18
- LIXT 71.83
- Support Level
- OP $1.07
- LIXT $4.28
- Resistance Level
- OP $1.21
- LIXT $4.85
- Average True Range (ATR)
- OP 0.12
- LIXT 0.58
- MACD
- OP 0.76
- LIXT 0.17
- Stochastic Oscillator
- OP 25.37
- LIXT 91.67
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.